In This Article:
HILLSIDE, NJ / ACCESS Newswire / May 14, 2025 / Integrated BioPharma, Inc. ((OTCQX:INBP)) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2025.
Revenue for the quarter ended March 31, 2025 was $13.9 million compared to $13.1 million for the quarter ended March 31, 2024, an increase of $0.8 million or 6.1%. The Company had operating income in the quarter ended March 31, 2025 of approximately $0.7 million compared to $0.4 million in the quarter ended March 31, 2024.
Revenue for the nine-month period ended March 31, 2025 was $40.2 million compared to $37.6 million for the nine-month period ended March 31, 2024, an increase of $2.6 million or 6.9%. The Company had operating income for the nine-month period ended March 31, 2025 of approximately $1.4 million and an operating loss of approximately $0.2 million for the nine-month period ended March 31, 2024.
For the quarters ended March 31, 2025 and 2024, the Company had net income of approximately $0.6 million and $0.3 million, respectively. The Company's net income per share of common stock and diluted net income per share of common stock for the quarters ended March 31, 2025 and 2024 were $0.02 and $0.01 per share of common stock, respectively.
For the nine-month periods ended March 31, 2025 and 2024, the Company had net income of approximately $1.0 million and a net loss of approximately $0.2 million, respectively. The Company's net income (loss) per share of common stock and diluted net income (loss) per share of common stock for the nine months ended March 31, 2025 and 2024 were $0.03 and $(0.01), respectively.
"Our revenues increased by 6.9% in the nine months ended March 31, 2025 compared to the comparable period a year ago. Our revenue from our two largest customers in our Contract Manufacturing Segment represented approximately 83% and 90% of total revenue in the nine-month period ended March 31, 2025 and 2024, respectively," stated the Co-Chief Executive Officers of the Company, Riva Sheppard and Christina Kay. "We are happy to report that while focusing on our core business we were able to expand our customer base over the past year and increase our revenue," the Co-CEOs further stated.
A summary of our financial results for the three months and nine months ended March 31, 2025 and 2024 follows:
INTEGRATED BIOPHARMA, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
(Unaudited)
| Three Months Ended | Nine Months Ended | |||||||||||||||
| March 31, | March 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Total revenue | $ | 13,947 | $ | 13,147 | $ | 40,178 | $ | 37,571 | ||||||||
| Cost of sales | 12,396 | 11,899 | 36,085 | 34,971 | ||||||||||||
| Gross profit | 1,551 | 1,248 | 4,093 | 2,600 | ||||||||||||
| Selling and administrative expenses | 812 | 893 | 2,662 | 2,751 | ||||||||||||
| Operating income (loss) | 739 | 355 | 1,431 | (151 | ) | |||||||||||
| Other income (expense), net | 39 | (3 | ) | 36 | 5 | |||||||||||
| Income (loss) before income taxes | 778 | 352 | 1,467 | (146 | ) | |||||||||||
| Income tax expense, net | 167 | 67 | 481 | 10 | ||||||||||||
| Net income (loss) | $ | 611 | $ | 285 | $ | 986 | $ | (156 | ) | |||||||
| Net income (loss) per share: | ||||||||||||||||
| Basic | $ | 0.02 | $ | 0.01 | $ | 0.03 | $ | (0.01 | ) | |||||||
| Diluted | $ | 0.02 | $ | 0.01 | $ | 0.03 | $ | (0.01 | ) | |||||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic | 30,300,720 | 30,099,610 | 30,190,869 | 30,054,883 | ||||||||||||
| Diluted | 31,514,591 | 30,744,222 | 30,960,916 | 30,054,883 | ||||||||||||
About Integrated BioPharma Inc. (INBP)